Pancreatic Disease Articles & Analysis
8 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. ...
Creative Enzymes is a leading biotechnology company supporting the development of diagnostic enzymes for kidney and pancreatic diseases. Pancreatitis is inflammation of the pancreatic tissue, which can be either acute or chronic. Pancreatic enzymes, including amylase, lipase, and trypsin, can be used to monitor ...
“Both have the potential to make major inroads against devastating diseases using novel approaches to drug delivery. We are excited to have them join in the vibrant ecosystem of the LabCentral community and look forward to watching as these companies move down the path toward ...
GI disorders include inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal disorders (FGID’s).1 GI dysfunctions are also prevalent during recovery from abdominal surgery which can lead to post-operative ileus (POI).2 Current motility technologies are typically limited in scope, invasive and only sample for a brief time ...
Abnormal blood lipid levels are usually associated with various diseases, such as hypertension, coronary arteries, hypothyroidism, type 2 diabetes, obesity, pancreatitis, etc. ...
The NTO design and the experimental in vivo results are promising and demonstrate evidence that the Vectron TTx delivers energy to produce deep therapeutic temperature elevations which could be extremely effective for treating pancreatic cancer and other disease within the pelvis and abdomen, commented Dr. ...
The first planned clinical target is pancreatic cancer, the most deadly of the common cancers with an 8% 5-year survival rate. ...